C

Cardiff Oncology

D

CRDF

USD

0.055

(2.2267%)

Market Closed

17,534.00

حجم التداول

-1.04

الربح لكل سهم

-

العائد الربحي

-2.750000

P/E

117,537,825.85

حجم السوق

اليوم

2.2267%

1 اسبوع

-0.980%

1 شهر

5.428%

6 اشهر

-48.045%

12 اشهر

56.832%

بداية السنة

71.769%

كل الوقت

-99.219%

أصول ذات صلة

Title:
Cardiff Oncology

Sector:

Healthcare

Industry:

Biotechnology

Cardiff Oncology Inc a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical program in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC").

هل تحتاج مساعدة او لديك استفسار؟

تواصل معنا